Regulatory Exclusivity: NEW CHEMICAL ENTITY
✉ Email this page to a colleague
Drugs with New Chemical Entity Regulatory Exclusivity
Click here to include patents covering these drugs in this list
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Exclusivity Expiration | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | DALVANCE | dalbavancin hydrochloride | POWDER;INTRAVENOUS | 021883-001 | May 23, 2014 | RX | Yes | Yes | ⤷ Sign Up | NEW CHEMICAL ENTITY | |
Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | POWDER;INTRAVENOUS | 205436-001 | Jun 20, 2014 | RX | Yes | Yes | ⤷ Sign Up | NEW CHEMICAL ENTITY | |
Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | TABLET;ORAL | 205435-001 | Jun 20, 2014 | RX | Yes | Yes | ⤷ Sign Up | NEW CHEMICAL ENTITY | |
Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | ⤷ Sign Up | NEW CHEMICAL ENTITY | |
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | ⤷ Sign Up | NEW CHEMICAL ENTITY | |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Exclusivity Expiration | >Patented / Exclusive Use |